

# Knockout Mouse Production and Phenotyping (KOMP<sup>2</sup>): Update and Envisioning a Possible Second Phase

National Institutes of Health  
Division of Program Coordination, Planning, and Strategic Initiatives  
Council of Councils  
September 5, 2014




National Institute on  
Deafness and Other  
Communication Disorders

# KOMP (2006-2011)

- *“...a high-throughput international effort to produce...knockouts for all mouse genes, and place these resources into the public domain.”*
- The KOMP was launched in 2006 by NIH
  - \$56.6 million over 5 years from the ICs
  - a goal of creating 8,500 ES cell lines
  - alleles are nulls or conditional-ready, contain reporter
- The EC launched EUCOMM, the European Conditional Mouse Mutagenesis Program in October 2005 (funded in Feb 2005)
  - 13 M Euros over 3 years
  - a goal of creating 8,000 mutants.
- KOMP and EUCOMM along with other international efforts formed the International Knockout Mouse Consortium (IKMC) and have jointly produced > 17,000 mutant ES cell lines and made them available from public repositories.

# KOMP - Goals and Progress



9090 KO lines produced and being distributed from the KOMP repository

Community uptake:

- 1250 orders for vectors

- 2512 orders for ES cells

- 980 orders for mice or germplasm


# Rationale for Large-scale Phenotyping

Supporting a broad phenotyping effort would provide the following advantages:

- Eliminate the redundancy and waste inherent in the “cottage industry” approach
- Each mutant mouse will be characterized for a broad set of phenotypes to allow direct comparisons & result in a thorough description of gene function.
- Novel genes will be brought to light that would otherwise be ignored
- Quality standards will be established and maintained, so the data will be of the highest reliability.
- The risk of not finding a phenotype will be greatly reduced.
- Important, but unpublishable, negative results will be captured.
- Potential for breakthrough discoveries

# Genentech/Lexicon Mouse Phenotype Project

472 Mouse knockouts were broadly phenotyped



Andy Peterson, Genentech

130 (27%) strains had 1 phenotype

245 (52%) strains had 2-5 phenotypes

Similar findings in EUMODIC and Sanger Mouse Phenotyping Program

# Co-Funding from Common Fund and ICs

## Funding:

NIH Common Fund – 50%  
Participating NIH ICs – 50%  
\$110M over five years


## Project Awards:

### Mouse Production and Phenotyping:

The Jackson Labs  
Baylor College of Medicine  
University of California, Davis

### Data Coordination Center and Database:

European Bioinformatics Institute



# KOMP2 Project Goals - (2011-2021)

- **Phase 1 (2011-2016): Phenotype up to 2,500 lines**
  - Pipeline development, logistics
  - Phenotype technology developments
  - Economies of scale
- **Phase 2 (2016-2021): Phenotype 6,000 mutants**
  - Business plan in preparation
- **Data freely available through a Data Coordination Center**
  - “One stop shop” Web Portal
- **Mice available through the global network of mouse repositories**
- **Coordinate with IMPC to achieve broad-based phenotyping of 20,000 mutants from the IKMC resource**
  - A collaborative activity of mouse centers worldwide

# Multiple Physiological Domains

## Neurological/ Behaviour

Open Field

Modified SHIRPA/Dysmorphology

Grip Strength

Acoustic Startle/PPI

Pain Test

## Metabolism

Weight

Calorimetry

Intraperitoneal Glucose Tolerance Test

Body Composition (DEXA)

Clinical Blood Chemistry

Insulin Blood Level

## Cardiovascular

ECG / Echo

Heart Weight

## Pulmonary

Challenge Whole Body Plethysmography

## Reproduction

Fertility

## Sensory

Auditory Brain Stem Response (2+2)

Slit Lamp

Ophthalmoscope

## Musculo- skeletal

Grip Strength

Body Composition (DEXA)

X-ray (5 + 5)

## Immune

Hematology

FACS analysis – blood/spleen

## General

Modified SHIRPA/Dysmorphology

Gross Pathology & Tissue Collection (2+2)


Tissue embedding & Block Banking (2+2)

Histopathology (2+2)  
- from blocks where required




# Phenotyping Pipeline

**KEY:** — HOM Viable line — HOM Lethal line - - - HET Viable line    Mandatory tests    Non-Mandatory tests    Tests in development or under consideration




7M + 7F Mutant Adult Mice




# Three new genes involved in deafness


*Lrig1* has moderate deafness (20-30 dB)



*Mcph1* has moderate deafness (25-30 dB)



*Spns2* has severe deafness (60-80 dB)



Plus: 9 further genes with possible mild hearing impairment (5-15 dB) and 20+ genes with possible amplitude or latency defects but normal thresholds

# KOMP/KOMP<sup>2</sup> Timeline

